TOKYO —

A groundbreaking study led by Director Eunjoon Kim at the Institute for Basic Science (IBS) Center for Synaptic Brain Dysfunctions has identified a novel therapeutic avenue for autism spectrum disorder (ASD) and other neurodevelopmental disorders. The research, published recently, pinpoints a specific glycine transporter, Slc6a20a (also known as SLC6A20), as a critical target for restoring the function of NMDA receptors (NMDARs), which are vital for brain cell communication, learning, and memory. This discovery offers a more precise and potentially safer approach compared to previous therapeutic attempts.

Decades-Long Quest for Improved NMDAR Function

The pursuit of treatments to enhance NMDAR function has been a significant focus in neuroscience for decades, driven by the receptor’s crucial role in cognitive processes and its known dysfunction in various neurological and psychiatric conditions. These conditions include autism spectrum disorder, schizophrenia, intellectual disability, and the autoimmune disorder NMDAR encephalitis. Despite extensive research, clinical trials aimed at boosting NMDAR activity have yielded inconsistent results, highlighting the need for more targeted interventions.

Historically, strategies to improve NMDAR function have revolved around increasing the availability of glycine, an essential co-agonist for NMDAR activation alongside glutamate. One prominent approach involved blocking GlyT1, another glycine transporter that regulates extracellular glycine levels. However, GlyT1 is widely distributed throughout the brain, including in critical brainstem regions responsible for regulating breathing and movement. This broad distribution meant that therapies targeting GlyT1 often led to limited therapeutic benefits and were frequently accompanied by significant, dose-limiting side effects. The limitations of this approach underscored the urgent need for a more selective target that could modulate NMDAR function without compromising essential physiological processes.

Identifying Slc6a20a: A More Precise Target

The breakthrough came with the identification of Slc6a20a as a distinct and more promising target. Unlike GlyT1, Slc6a20a’s expression is primarily concentrated in brain regions critically involved in higher cognitive functions, such as the cerebral cortex and the hippocampus. This more restricted anatomical distribution suggests that targeting Slc6a20a could allow for the enhancement of NMDAR activity specifically within these cognitive circuits, thereby minimizing the risk of adverse effects on other vital brain functions.

The research team, led by Director Kim, hypothesized that reducing the activity of Slc6a20a could indirectly lead to an increase in synaptic glycine levels, thereby boosting NMDAR function. This hypothesis was based on the understanding that transporters regulate the concentration of their substrates in specific locations, and altering their activity could fine-tune these concentrations.

The Antisense Oligonucleotide (ASO) Approach

To test their hypothesis, the researchers employed a sophisticated gene-silencing technique: antisense oligonucleotides (ASOs). ASOs are short, synthetic strands of nucleic acids designed to bind to specific messenger RNA (mRNA) molecules, preventing the production of the corresponding protein. In this study, ASOs were designed to specifically reduce the expression of the Slc6a20a gene.

The experimental validation was conducted using mouse models engineered with mutations in the SHANK2 and SHANK3 genes. These genes are widely recognized as major genetic contributors to autism spectrum disorder and are also implicated in other neurodevelopmental conditions, including Phelan-McDermid syndrome. By using these established genetic models of autism, the researchers aimed to determine if targeting Slc6a20a could ameliorate autism-related behavioral and neurobiological deficits.

Restoring NMDAR Function and Improving Behavioral Phenotypes in Mice

The results from the mouse studies were highly encouraging. Administration of the Slc6a20a ASO treatment successfully restored NMDAR activity in the brains of these genetically modified mice. This restoration of receptor function was accompanied by significant improvements in autism-related behavioral phenotypes. Specifically, the treated mice exhibited amelioration of deficits in social interaction and social communication, as well as a reduction in repetitive behaviors – core diagnostic features of ASD.

A particularly striking finding was that the beneficial effects of the treatment were observed even in adult mice. This suggests that the therapeutic potential of modulating NMDAR function via Slc6a20a might extend beyond the critical early developmental periods, offering hope for interventions in individuals who have already passed through major stages of brain development. This is a significant point, as many neurodevelopmental disorders are currently managed rather than cured, with interventions often most effective when initiated early.

Unraveling the Molecular Mechanism: Phosphorylation Modulation

Further investigation into the molecular underpinnings of the treatment’s efficacy revealed a nuanced mechanism of action. Using advanced large-scale phospho-proteomic analyses, the researchers discovered that the Slc6a20a ASO therapy did not significantly alter the total abundance of proteins within the targeted brain regions. Instead, the therapy was found to correct aberrant phosphorylation patterns in key proteins involved in synaptic signaling and NMDAR regulation.

Phosphorylation, a process where a phosphate group is added to a protein, acts as a molecular switch that can alter a protein’s activity, stability, or localization. The finding that the treatment restored normal phosphorylation patterns suggests that the therapy works by fine-tuning the functional state of existing proteins rather than simply increasing or decreasing their overall quantity. This represents a more subtle and potentially more robust way to restore proper neuronal function.

Validation in Human Brain Organoids: Bridging the Gap

To assess the translational potential of their findings, the research team extended their investigations to human brain models. They utilized CRISPR gene editing technology to generate human cortical organoids – three-dimensional, self-organizing structures derived from human stem cells that mimic key aspects of the developing human brain. These organoids were engineered to carry mutations in the SHANK2 or SHANK3 genes, mirroring the genetic basis of some forms of ASD.

Consistent with the findings in mouse models, these human organoids exhibited reduced NMDAR activity. Crucially, when treated with an ASO specifically designed to target the human SLC6A20 gene, NMDAR function was restored to levels closely approximating those observed in healthy control organoids. This successful replication of the therapeutic effect in human brain organoids provides strong preclinical evidence for the potential efficacy of this approach in humans.

Director Eunjoon Kim commented on the significance of this validation: "Unlike gene re-expression strategies, SLC6A20 inhibition works by modulating endogenous signaling pathways and may offer a more practical therapeutic route. The fact that the effect was reproduced not only in mice but also in human cortical organoids suggests that this approach may represent a promising therapeutic strategy for neurodevelopmental disorders characterized by NMDA receptor hypofunction."

Durability and Broad Applicability of the Treatment

Further analysis of the ASO treatment in mice revealed encouraging data regarding its durability. A single administration of the Slc6a20a ASO demonstrated sustained effectiveness for at least eight weeks. During this observation period, no detectable adverse effects were observed in the treated mice, underscoring the potential safety profile of this targeted intervention.

While the primary focus of this study was on autism spectrum disorder, the implications of these findings extend to a broader spectrum of neurodevelopmental and neuropsychiatric conditions. The underlying mechanism – restoring NMDAR function – is relevant to other disorders characterized by NMDAR hypofunction, including schizophrenia and certain forms of intellectual disability. Therefore, the identification of SLC6A20 as a therapeutic target holds promise for developing treatments that could benefit a wider patient population.

Broader Implications for Neurodevelopmental Disorders

The research by Director Kim’s team represents a significant step forward in the understanding and potential treatment of complex neurodevelopmental disorders. By moving beyond broad-acting interventions to a precisely targeted approach, the study offers a paradigm shift in therapeutic strategy. The focus on modulating the functional state of existing proteins through phosphorylation correction, rather than simply altering protein levels, suggests a more refined and potentially more effective way to rebalance disrupted neuronal circuitry.

The success in both animal models and human organoids provides a robust foundation for future clinical development. The sustained efficacy and apparent lack of adverse effects in preclinical studies are particularly encouraging for advancing this therapy towards human trials.

Future Directions and Clinical Translation

The path from preclinical research to approved therapy is often long and complex. However, the compelling data generated by this study positions SLC6A20 as a highly promising target for further investigation. Future research will likely focus on optimizing ASO delivery methods to ensure efficient penetration into the human brain and on conducting rigorous safety and efficacy studies in human clinical trials.

The potential impact of this research is profound. If successfully translated to the clinic, treatments targeting SLC6A20 could offer much-needed therapeutic options for individuals with autism spectrum disorder and other NMDAR hypofunction-related conditions, potentially improving cognitive function, social engagement, and overall quality of life. This discovery underscores the continued importance of fundamental research into brain function and the intricate molecular mechanisms that govern neurological health.